No abstract

Background Melasma treatment is difficult due to extended treatment periods, suboptimal adherence, inconsistent results, and frequent relapses. Kojic acid has been shown to be effective in reducing melasma severity and is now increasingly used in cosmetic treatments. Aims The purpose of the present study was to evaluate the effectiveness of a new cosmetic treatment for melasma at 45 and 90 days. Methods Multicenter prospective study across 20 dermatology clinics/ambulatories. One hundred patients with mild‐to‐moderate melasma were evaluated. The primary endpoints were changes in mean modified melasma area and severity index (mMASI) score and patient‐reported satisfaction at 45 and 90 days. Results The mean age of patients was 45.19 ± 11.5 years. Most patients were female and Caucasian. Patients presented mixed (65%), epidermal (26%), and dermal (4%) types of melasma. Triggering factors were hormonal contraception (33%), pregnancy (31%), and pharmacological treatment (11%); mean disease duration was 6.7 ± 6.8 years. Overall, a statistically significant decrease in mean mMASI scores was seen at 45 (2.19 ± 0.182 vs 3.29 ± 0.267, P < .0001) and 90 days (1.27 ± 0.128 vs 3.29 ± 0.267, P < .00001). The highest reduction in mMASI scores was observed in patients with dermal melasma. IGA scores showed a statistically significant improvement in pigmentation at 90 days (P < .00001). Conclusion The novel cosmetic treatment was associated with the improvement of melasma, as assessed by mMASI.

Based on clinical features, infantile seborrheic dermatitis (ISD) can be classified as follows: true seborrheic dermatitis (SD), psoriasiform seborrheic dermatitis (Psor SD), and erythrodermic seborrheic dermatitis. We reviewed the records of 72 children who had been affected by ISD several years earlier to investigate the evolution of disease, to evaluate the patients for the presence of new skin lesions, and to study family histories with respect to these conditions. In addition, we attempted to determine if there is any connection among the initial features of ISD and the types of skin lesions, and atopy or psoriasis. On reexamination, our patients previously diagnosed as having SD showed a larger variety of new skin lesions than those who had Psor SD, and 15% had developed atopic dermatitis. Atopic dermatitis was not present at follow-up in the children with previously diagnosed Psor SD. Psoriatic lesions were present in similar percentages in both groups at the time of reevaluation. Investigation of family history was not useful in predicting later development of psoriasis or atopic dermatitis. We conclude that the initial clinical features of ISD may be of prognostic value, and that SD and Psor SD are probably two different clinical entities.

The term 'ultrapure water' is a common way to define water used for on-line treatments: it refers to the absence of chemical, organic and microbiological contamination. To be more accurate in definition, every known and potential contaminant has to be fixed at its limit value. AAMI recommendations and various Pharmacopoeias have set limits for dialysate based on traditional dialysis treatments, but on-line treatments should also be regulated by guidelines for infusion solutions. Modern water treatment technology allows us to obtain a proper chemical quality both for dialysate and infusion solutions in on-line dialysis. Technology alone, however, cannot guarantee adequate microbiological quality if water treatment is not linked to the appropriate maintenance, monitoring, cleaning and sanitizing procedures. On-line dialysis treatments, as well as high-flux dialysis, use the monitor as an on-site pharmaceutical factory where sterilization by filtration forces nephrologists to look for procedures to keep sterile water sterile.

No abstract